- High Concentrations of Pamidronate in Bone Weaken the Mechanical Properties of Intact Femora in a Rat Model
-
Yang KH, Won JH, Yoon HK, Ryu JH, Choo KS, Kim JS
- KMID: 2158171
- Yonsei Med J.
- 2007 Aug;48(4):653-658.
- doi: 10.3349/ymj.2007.48.4.653
PURPOSE: Bisphosphonates have been used to treat osteoporosis for more than ten years. However, complications associated with long-term administration of bisphosphonates, such as nonunion after pelvic insufficiency fracture or osteonecrosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic Polymorphism of Geranylgeranyl Diphosphate Synthase (GGSP1) Predicts Bone Density Response to Bisphosphonate Therapy in Korean Women
-
Choi HJ, Choi JY, Cho SW, Kang D, Han KO, Kim SW, Kim SY, Chung YS, Shin CS
- KMID: 1126023
- Yonsei Med J.
- 2010 Mar;51(2):231-238.
- doi: 10.3349/ymj.2010.51.2.231
PURPOSE: Genetic factor is an important predisposing element influencing the susceptibility to osteoporosis and related complications. The purpose of the present study is to investigate whether genetic polymorphisms of farnesyl... -
- CITED
-
- Close
- SHARE
-
- Close
- Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation
-
Moon MH, Jeong JK, Seo JS, Seol JW, Lee YJ, Xue M, Jackson CJ, Park SY
- KMID: 1109402
- Exp Mol Med.
- 2011 Mar;43(3):138-145.
- doi: 10.3858/emm.2011.43.3.016
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily of cytokines, is one of the most promising candidates for cancer therapeutics. However, many osteosarcomas are resistant... -
- CITED
-
- Close
- SHARE
-
- Close
